Latest news with #DRP
India Gazette
4 hours ago
- Business
- India Gazette
Dharavi Redevelopment: Over 75 per cent tenants qualify for new homes
Mumbai (Maharashtra) [India], July 2 (ANI): Residents of Dharavi are waiting with bated breath as the Dharavi Redevelopment Project (DRP), along with the Government of Maharashtra, has begun releasing the Draft Annexure-II in phases. In the first such list published for Sector 6 (Meghwadi and Ganesh Nagar), over 75 per cent of tenement holders have qualified for new homes under the redevelopment scheme, according to data released by the DRP. The balance would get a qualified basis, additional checks and documents sought. Out of a total of 505 tenements, 31 tenements are yet to submit any documents, 137 cases are pending verification by BMC, which the DRP is pursuing, and the remaining 38 are amenity structures. Among the remaining 299 tenements, 229 have been found eligible for new homes under various criteria. The remaining 70 are in the process of submitting additional documents to validate their eligibility. DRP CEO SVR Srinivas assured that every resident will get a house either inside or outside Dharavi based on their eligibility status. 'I would like to reiterate that the Dharavi redevelopment is the most inclusive project ever contemplated in SRA history, where every resident is going to get a house. Not just that, all commercial units, whether eligible or ineligible, will get spaces inside Dharavi itself,' Srinivas said. He further explained that commercial units that are eligible will, in any case, get free in-situ spaces inside Dharavi. In fact, a proposal has been made to the government to accommodate ineligible commercial units as well, on a rental basis, inside Dharavi. 'The 10 per cent commercial space reserved in every society can be given on a rental basis to ineligible commercial units so that they can sustain their livelihoods in Dharavi itself. We have already made this proposal,' Srinivas said. As per the Annexure-II data, 170 ground-floor tenements, including residential, commercial and residential/commercial, have all met the eligibility criteria and are entitled to new homes either within or outside Dharavi. Of these, 157 tenements came into existence before January 1, 2000, and are entitled to 350 sq ft homes within Dharavi. The remaining 13 are considered Shashulk Eligible, meaning they are entitled to 300 sq ft homes outside Dharavi at a subsidised cost of Rs 2.5 lakh, having settled in Dharavi before Jan 1, 2011. In a significant step, the inclusion of upper-floor tenement holders, typically disqualified under all other slum rehabilitation schemes, is a true mark of the present government and DRP's promise for inclusivity. As per the data, 59 upper-floor tenements have qualified for new homes under the DRP's unique 'hire-purchase' scheme. These residents will receive 300 sq ft homes on rent for 12 years, after which they will become legal owners. They may also choose to buy the home outright at a government-decided rate at any time during the 12-year period. Typically, under other SRA schemes, those who settle in the ground floor after 2011 are excluded from redevelopment benefits, and all upper-floor residents face outright eviction. However, DRP has ensured that all such residents are also provided with new and modern homes outside Dharavi but within the Mumbai Metropolitan Region (MMR). These colonies will be modern and will be maintained free of cost for 10 years. The DRP has invited tenement holders to submit their suggestions or objections regarding the Draft Annexure II. Submissions can be made to the DRP office or by email to [email protected]. The deadline is July 5, 5.30 PM. (ANI)
Time of India
6 hours ago
- Business
- Time of India
First eligibility list for Dharavi redevelopment released
The Dharavi Redevelopment Project (DRP) has released its first eligibility list, with over 75 per cent of tenement holders qualifying for new homes under the ambitious slum redevelopment scheme, according to data released by the DRP. All bona fide residents who settled in Dharavi before January 1, 2000, are eligible for a 350 sq ft flat within Dharavi. All such residents will qualify for the resettlement unless they do not provide documents. Those who settled between January 1, 2000, and January 1, 2011, may receive 300 sq ft units outside Dharavi at alternative locations. The first list identifies 505 households from Meghwadi and Ganesh Nagar in Mahim as eligible for rehabilitation. In the first list published for 505 households of Sector 6 (Meghwadi and Ganesh Nagar in Mahim), over 75 per cent of tenement holders have qualified for new homes under the redevelopment scheme, according to data released by the DRP. The balance would get qualified, based on additional checks and documents sought. Live Events Out of a total of 505 tenements, 31 tenements are yet to submit any documents, 137 cases are pending verification by BMC, which the DRP is pursuing, and the remaining 38 are amenity structures. Among the remaining 299 tenements, 229 have been found eligible for new homes under various criteria. The remaining 70 are in the process of submitting additional documents to validate their eligibility. DRP CEO SVR Srinivas assured that every resident will get a house either inside or outside Dharavi, basis their eligibility status. "I would like to reiterate that the Dharavi redevelopment is the most inclusive project ever contemplated in SRA history, where every resident is going to get a house. Not just that, all commercial units, whether eligible or ineligible, will get spaces inside Dharavi itself." He further explained that commercial units that are eligible will, in any case, get free in-situ spaces inside Dharavi. In fact, a proposal has been made to the government to accommodate ineligible commercial units as well, on a rental basis, inside Dharavi. "The 10 per cent commercial space reserved in every society can be given on a rental basis to ineligible commercial units so that they can sustain their livelihoods in Dharavi itself. We have already made this proposal." As per the Annexure-II data, 170 ground-floor tenements, including residential, commercial and residential/commercial, have all met the eligibility criteria and are entitled to new homes either within or outside Dharavi. Of these, 157 tenements came into existence before January 1, 2000, and are entitled to 350 sq ft homes within Dharavi. The remaining 13 are considered Shashulk Eligible, meaning they are entitled to 300 sq ft homes outside Dharavi at a subsidised cost of Rs 2.5 lakh, having settled in Dharavi before January 1, 2011. In a significant step, the inclusion of upper-floor tenement holders, typically disqualified under all other slum rehabilitation schemes, provides inclusivity. As per the data, 59 upper-floor tenements have qualified for new homes under the DRP's unique 'hire-purchase' scheme. These residents will receive 300 sq ft homes on rent for 12 years, after which they will become legal owners. They may also choose to buy the home outright at a government-decided rate at any time during the 12-year period. Typically, under other slum rehabilitation schemes, those who settle in the ground floor after 2011 are excluded from redevelopment benefits, and all upper-floor residents face outright eviction. However, DRP has ensured that all such residents are also provided new and modern homes outside Dharavi, but within the Mumbai Metropolitan Region (MMR). These colonies will be modern and will be maintained free of cost for 10 years. The DRP has invited tenement holders to submit their suggestions or objections regarding the Draft Annexure-II. Submissions can be made to the DRP office by July 5.
Associated Press
2 days ago
- Business
- Associated Press
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP® platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'This latest patent acceptance from Australia represents another important achievement in our efforts to secure international IP protection for our DRP® technology. As we continue advancing stenoparib through Phase 2 trials toward U.S. regulatory approval, we are also building a robust intellectual property position in key global markets.' Allarity previously secured a European patent for the Stenoparib DRP® and holds 18 granted patents for drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP® remain pending in the U.S., Canada, Japan, China, and India. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the Australian patent for the Stenoparib DRP®; the anticipated contribution of this patent to the Company's global intellectual property strategy; and the Company's ability to advance and commercialize stenoparib in Australia and other key markets. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the potential for opposition to the patent grant; changes in regulatory timelines or requirements; failure to obtain regulatory approval for stenoparib or its companion diagnostic; and risks inherent in developing and commercializing biopharmaceutical products. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected] Attachment
Indian Express
3 days ago
- Business
- Indian Express
BMC extends deadline for waste bioremediation at Deonar for a third time
For the third time, the Brihanmumbai Municipal Corporation (BMC) has extended its deadline for the Rs 2,368 crore tender to appoint a contractor to carry out bioremediation of 185 lakh tonnes of waste and reclaim 110 hectare of land at the Deonar dumpsite over a period of three years. Bioremediation is a process involving treating garbage with the help of natural elements like air, sunlight, and microorganisms. Over time, as the biodegradable waste decomposes, the remaining non-biodegradable extracts are either recycled or treated artificially. The process of bioremediation is proposed at the Deonar dumpsite, which is among one of the sites that have been selected by the state government for constructing housing tenements for the Dharavi Redevelopment Project (DRP) – a venture steered by the Adani group and Maharashtra government's Slum Rehabilitation Authority (SRA). Earlier on May 14, the civic body had floated a tender inviting bidders to clear the Deonar dumpsite through bioremediation with a deadline of June 3, which was later extended to June 23 and further, revised to July 1. On Saturday, for the third time in a month, the BMC has again extended the deadline for the bidders to July 4. In the revised corrigendum, the civic body has revised the conditions, permitting a price escalation of five percent after 2 years. According to officials, the deadline has been revised owing to extension requested by bidders amid several concerns. For the record, at least 23 bidders had come forward and expressed interest during a pre-bid meeting convened earlier. 'Primarily, there are two major concerns which have been raised by the bidders. Firstly, the concerns pertain to the price as there was no provision for price escalation in the initial tender clause. Furthermore, many interested bidders had requested allocation of more time to collect and submit the documents. Another reason is the unique nature of the work stipulated in the tender, wherein nearly 2 crore metric tonnes of legacy waste has to be cleared over a period of three years,' said a civic official. 'This is our final corrigendum, following which no other extensions will be granted.' According to the civic data, of the 1.85 crore metric tonnes of waste which is currently stacked at the dumpsite, nearly 48 percent comprises construction debris, 41 percent is inert waste while 10 percent is accounted for by dry, miscellaneous waste.
New Straits Times
6 days ago
- Business
- New Straits Times
Westports sails strong despite global headwinds
KUALA LUMPUR: The global economic slowdown is unlikely to significantly impact Westports Holdings Bhd's operational growth in the near term, according to Hong Leong Investment Bank Bhd (HLIB). The firm said Westports is currently operating at an optimal utilisation rate of 80 per cent of its 14 million twenty-foot equivalent unit (TEU) capacity. The port operator has indicated expectations of mid-single-digit growth in container throughput through to 2027, with additional capacity projected to come online by mid-2028. "As such, we do not anticipate the expected global economic slowdown to significantly impact market expectations regarding Westports' near-term operational growth," HLIB said in a research note. It maintained a "buy" call on Westports with a higher target price of RM6.08 from RM5 previously, post-earnings revision to account for the approved tariff hikes. "We expect earnings sustainability and resilient volume movements, despite concerns over global trade slowdown. "Also, the proposed dividend reinvestment plan (DRP) is poised to enhance shareholder value while supporting medium-term capital expenditure requirements," it said. Westports has implemented a DRP, offering shares at a discount of less than 10 per cent to the five-day volume-weighted average market price prior to the price-fixing date. The DRP proceeds will help support the company's ongoing expansion plans while maintaining its strong financial standing. "Major shareholders, including Pembinaan Redzai along with its affiliate Semakin Ajaib, and South Port Invest, have committed to participate in the DRP, collectively representing 69.1 per cent of the company's total share capital," it added. On the port tariff hike, HLIB said the increase will improve Westports' earnings and cash flow and, together with its DRP, support the financial sustainability of its ongoing expansion plan. The Transport Ministry has approved port tariff hikes for Westports, effective July 15, 2025, which will be implemented in stages until January 1, 2027. Container handling charges are expected to jump by 30 per cent, while conventional and marine services will increase by 15 per cent. On capacity expansion, Westports is currently executing a major expansion plan to double its container handling capacity to 28 million TEUs, covering the development of terminals CT10 to CT17. HLIB said the initial phase, CT10 and CT11, is progressing well, with dredging and land reclamation works already underway. "Construction is scheduled to begin in the first quarter of 2027, with CT10 expected to be operational by mid-2028 and CT11 by the end of 2029. "The recently approved tariff revision and the implementation of DRP will ensure the financial sustainability of these long-term expansion efforts," it added.
